Eszopiclone - CAS 138729-47-2
Catalog number: 138729-47-2
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C17H17ClN6O3
Molecular Weight:
388.81
COA:
Inquire
Targets:
GABA Receptor
Description:
Eszopiclone is an active stereoisomer of zopiclone with hypnotic and sedative activity and without significant anxiolytic activity. Eszopiclone is a GABA A receptor agonist. It is able to bind to and activate the omega-1 subtype of the alpha subunit of the GABA receptor complex. This leads to the opening of chloride channels, causing hyperpolarization, inhibition of neuronal firing, and enhancement of the inhibitory effect of GABA. Eszopiclone is an approved for the treatment of insomnia. It is a controlled substance (depressant) in the US but not in Canada.
Purity:
98%
Appearance:
White To Pale Yellow Solid
Synonyms:
Lunesta; (S)-Zopiclone; Estorra; Esopiclone;[(7S)-6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate
Solubility:
Acetone, Chloroform, Ethanol, Phosphate Buffer (pH 3.2),
Storage:
-20°C Freezer
MSDS:
Inquire
Application:
Insomnia
Quality Standard:
In-house standard
Shelf Life:
2 month in rt, long time
Quantity:
Milligrams-Grams
Boiling Point:
No Data Available
Melting Point:
202-204°C
InChIKey:
GBBSUAFBMRNDJC-INIZCTEOSA-N
InChI:
1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3/t16-/m0/s1
Canonical SMILES:
CN1CCN(CC1)C(=O)O[C@H]2c3c(nccn3)C(=O)N2c4ccc(cn4)Cl
Current Developer:
Eisai Co Ltd; Sepracor; Sunovion Pharmaceuticals
1.Dissection of the factors driving the placebo effect in hypnotic treatment of depressed insomniacs.
McCall WV;D'Agostino R Jr;Rosenquist PB;Kimball J;Boggs N;Lasater B;Blocker J Sleep Med. 2011 Jun;12(6):557-64. doi: 10.1016/j.sleep.2011.03.008. Epub 2011 May 20.
OBJECTIVES: ;Our prior work has shown that there is improvement in self-reported sleep in persons receiving placebo in hypnotic clinical trials. We examined the components of the "placebo response" in a hypnotic clinical trial.;METHODS: ;This was an exploratory analysis of a randomized, double-blind clinical trial of eszopiclone versus placebo in the treatment of persons with depression and insomnia who were also receiving fluoxetine at a clinic of a teaching hospital. Sixty adults with both depression and insomnia symptoms, who were free of significant primary sleep disorders, received open-label fluoxetine for 9weeks. Patients were further randomized 1:1 to receive either masked eszopiclone 3mg or placebo at bedtime after the first week of fluoxetine. We examined the respective contributions of three factors associated with the "placebo effect": (1) regression to the mean, (2) expectancy, and (3) social desirability.;RESULTS: ;There was evidence for regression to the mean for the continuous measurement of the Insomnia Severity Index (ISI) and the Hamilton Depression Rating Scale. There was evidence for expectancy in self-reported Wake After Sleep Onset, continuous measurement of ISI, and dichotomous remission/non-remitter measurement of ISI.
2.The modulation of synaptic GABA(A) receptors in the thalamus by eszopiclone and zolpidem.
Jia F;Goldstein PA;Harrison NL J Pharmacol Exp Ther. 2009 Mar;328(3):1000-6. doi: 10.1124/jpet.108.146084. Epub 2008 Nov 25.
Eszopiclone (Lunesta; Sepracor, Marlborough, MA) and zolpidem [N,N,6-trimethyl-2-(4-methylphenyl)-imidazo(1,2-a)pyridine-3-acetamide] are among the most commonly prescribed hypnotics in use in the United States. The thalamus plays a pivotal role in sleep regulation and rhythmicity. Two distinct subtypes of synaptic GABA(A) receptors (GABA(A)-Rs), alpha(1)beta(2)gamma(2) and alpha(3)beta(3)gamma(2), are expressed in thalamocortical relay neurons and in interneurons of the RTN (reticular thalamic nucleus), respectively. Thalamocortical neurons also express extrasynaptic GABA(A)-Rs composed of alpha(4)beta(2)delta subunits. In this study, we compared the effects of eszopiclone and zolpidem on miniature inhibitory postsynaptic currents (IPSCs), spontaneous IPSCs, and tonic inhibition in the mouse thalamus. Eszopiclone (0.1-1 microM) slowed the decay phase of IPSCs recorded from RTN neurons, whereas zolpidem was less effective and increased the decay time constant only at > or = 0.3 microM. IPSCs of RTN neurons were more sensitive to eszopiclone than zolpidem at all concentrations tested. On the other hand, IPSCs of relay neurons in the ventrobasal nucleus (VB) were more sensitive to zolpidem than eszopiclone.
3.Safety, Tolerability and Efficacy of Drugs for Treating Behavioural Insomnia in Children with Attention-Deficit/Hyperactivity Disorder: A Systematic Review with Methodological Quality Assessment.
Anand S;Tong H;Besag FMC;Chan EW;Cortese S;Wong ICK Paediatr Drugs. 2017 Jun;19(3):235-250. doi: 10.1007/s40272-017-0224-6.
OBJECTIVE: ;A large proportion of paediatric patients with attention-deficit/hyperactivity disorder (ADHD) have associated sleep problems which not only affect the child's wellbeing but also impact family functioning. Management of sleep problems is consequently an important aspect of overall ADHD management in paediatric patients. Although some drugs are being used off-label for the management of paediatric insomnia, there is scant clinical evidence supporting their use. Our aim was to identify and assess the quality of published studies reporting the safety, tolerability and efficacy of drugs used for treating behavioural insomnia in children with ADHD.;METHODS: ;After an initial screen to determine which drugs were most commonly used, we conducted a systematic review of English-language publications from searches of PubMed, EMBASE, PsycINFO and two trial register databases to February 2017, using keywords 'clonidine', 'melatonin', 'zolpidem', 'eszopiclone', 'L-theanine', 'guanfacine', 'ADHD', 'sleep disorder' and 'children'. For quality assessment of included studies, we used the CONSORT checklist for randomised control trials (RCTs) and the Downs and Black checklist for non-RCTs.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related GABA Receptor Products


CAS 152273-12-6 U-93631

U-93631
(CAS: 152273-12-6)

U 93631 is a ligand at the picrotoxin site of GABA(A) receptors, allosterically antagonizing GABA-induced Cl- currents. U-93631 causes rapid decay of gamma-amin...

CAS 84379-13-5 Bretazenil

Bretazenil
(CAS: 84379-13-5)

Bretazenil is a partial agonist at the GABAA benzodiazepine site (EC50 = 10 nM at α1β1γ2 receptors) that potentiates GABA responses on α4β3γ2 cells. Bretazenil ...

CAS 917393-39-6 Lorediplon

Lorediplon
(CAS: 917393-39-6)

Lorediplon is a hypnotic drug acting as a GABAA receptor modulator, differentially active at the alpha1-subunit. It is a novel nonbenzodiazepine of the pyrazolo...

CAS 71424-95-8 3-Methyl-GABA

3-Methyl-GABA
(CAS: 71424-95-8)

3-Methyl-GABA is an activator of GABA aminotransferase.

CAS 339-72-0 L-Cycloserine

L-Cycloserine
(CAS: 339-72-0)

L-Cycloserine is excitatory amino acid, an antibiotic effective against Mycobacterium tuberculosis.

CAS 64603-91-4 Gaboxadol

Gaboxadol
(CAS: 64603-91-4)

Gaboxadol is a GABA agonist. It was a non-opioid analgesic and a novel type of hypnotic. It was first synthesized in 1977 by the Danish chemist Povl Krogsgaard-...

CAS 1215833-62-7 DMCM hydrochloride

DMCM hydrochloride
(CAS: 1215833-62-7)

DMCM hydrochloride is a benzodiazepine inverse agonist exhibiting anxiogenic and potent convulsant activity.

CAS 160296-13-9 SB 205384

SB 205384
(CAS: 160296-13-9)

SB 205384 is a GABAA receptor modulator. SB 205384 potentiates α6, α3 and α5-subunit-containing receptors (EC50 = 280, 695 and 730 nM, respectively). It exhibit...

CAS 6001-74-7 Chlormethiazole hydrochloride

Chlormethiazole hydrochloride
(CAS: 6001-74-7)

Chlormethiazole hydrochloride is the hydrochloride salt of chlormethiazole, which is a GABAA agonist. It is a useful research chemical and is used in the study ...

CAS 128201-89-8 N-ArachidonylGABA

N-ArachidonylGABA
(CAS: 128201-89-8)

N-ArachidonylGABA is first isolated from bovine brain. It was also found to inhibit normal responses to pain in vivo, but has not been fully characterized to da...

CAS 194098-25-4 CP-409092

CP-409092
(CAS: 194098-25-4)

CP-409092 is a GABA(A) partial agonist developed for the treatment of General Anxiety Disorder (GAD) and presents an interesting phenomenon of human pharmacokin...

CAS 156685-94-8 Org 20599

Org 20599
(CAS: 156685-94-8)

Org 20599 is an anaesthetic steroid. It has modulatory effects on GABAA receptors. Org 20599 is a potential theraputic for migraines and headaches.

CAS 133737-32-3 Pagoclone

Pagoclone
(CAS: 133737-32-3)

Pagoclone, an active (+)-enantiomer of the racemate RP 59037, is a ubtype selective partial agonist at GABAA receptor and used for the treatment of panic and an...

CAS 53552-05-9 (-)-Bicuculline methochloride

(-)-Bicuculline methochloride
(CAS: 53552-05-9)

(-)-Bicuculline methochloride is the methochloride salt of (+)-bicuculline, which is a potent antagonist of GABAA receptors.

CAS 110283-79-9 CI966

CI966
(CAS: 110283-79-9)

CI966 is a highly potent and selective blocker of the GABA transporter 1 (GAT-1) with IC50 value of 0.26 µM acting as a central nervous system depressant. It ha...

CAS 1236105-75-1 PHP 501 trifluoroacetate

PHP 501 trifluoroacetate
(CAS: 1236105-75-1)

PHP 501 trifluoroacetate is potent GABAA antagonist (Ki = 0.0028 μM at rat GABAA receptors; IC50 = 0.024 μM at human α1β2γ2 GABAA-expressing tsA201 cells), with...

CAS 38090-53-8 TACA

TACA
(CAS: 38090-53-8)

TACA, the trans-isomer of CACA, is a potent GABAA and GABAC agonist, GABA uptake inhibitor and substrate for GABA-T. It also acts as a GABAA-ρ agonist.

CAS 1852-38-6 Pregnenolone sulfate sodium salt

Pregnenolone sulfate sodium salt
(CAS: 1852-38-6)

Pregnenolone sulfate, a metabolite of the natural steroid hormone pregnenolone, is a neurosteroid that has been demonstrated to antagonize the GABAA receptor ch...

CAS 233275-76-8 MK 0343

MK 0343
(CAS: 233275-76-8)

MK 0343, also known as MRK-409, is a subtype-selective GABAA partial agonist (Ki values are 0.21, 0.22, 0.23 and 0.40 for α3, α1, α5 and α2 respectively). MK-03...

CAS 142720-24-9 FGIN-1-27

FGIN-1-27
(CAS: 142720-24-9)

FGIN-1-27 is a high affinity agonist of mitochondrial benzodiazepine receptors (PBR) binding to benzodiazepine receptors on mitochondrial membranes. FGIN-1-27 i...

Chemical Structure

CAS 138729-47-2 Eszopiclone

Quick Inquiry

Verification code

Featured Items